Capped and uncapped antibody cysteines, and their use in antibody-drug conjugation
An antibody production process in mammalian cells in which engineered unpaired cysteine residues are post-translationally modified and capped with particular chemical entities, which capped antibodies are well suited to further site-specific conjugation steps to form antibody-drug conjugates (ADCs) or protein drug conjugates; ADCs produced using these capped antibodies including in particular ADCs formed by the selective reduction of the capped antibodies' cysteine residues, and ADCs formed using chemical handles such as aldehyde/azide/alkyne biorthogonal groups, which permit additional drug conjugation chemistry; and uncapped antibodies produced by cells in low cysteine, cysteine and glutathione media, and ADCs produced via direct conjugation to these uncapped antibodies.
Pfizer Inc.
A A A A C C A A C C C C C
A61K A61K A61K A61K C07K C07K A61K A61K C07K C07K C07K C07K C07K
inventional inventional inventional inventional additional inventional inventional inventional additional additional additional additional inventional
Will Leo Joseph Wenge Tao Xiaotian Amarnauth Shastrie Ronald William
Somers Letendre Wang He Zhong Prashad Kriz